A Phase 2a, Multi-Center, Open-Label Study to Compare Two Dosing Regimens of 177Lu-TLX250 (lutetium (177Lu) girentuximab tetraxetan) in Participants with Carbonic Anhydrase IX (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC)
Treatments
Therapies:
Antibody-based positron emission tomography (PET) imaging modality used to non-invasively detect clear cell renal cell carcinoma (ccRCC); Targeted delivery of beta radiation to CAIX-expressing tumor cells via antibody
Medications:
177Lu-TLX250 (); 89Zr-TLX250 ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
